Webinars

May 22, 2024 9:00am BST, 4:00pm SGT

Transforming DR-TB Detection with tNGS: Evidence, Cost Analysis, and Implementation Considerations

Sponsored by: Illumina

12 +50pts

Speakers

Anita Suresh

Head of Genomics & Sequencing Unit, FIND, Geneva
BIOGRAPHY
Dr. Alice Zwerling

Associate Professor, School of Epidemiology and Public Health, University of Ottawa
BIOGRAPHY
Dr. Shaheed Vally Omar

Centre Head, Centre for Tuberculosis, National Institute for Communicable Diseases (NICD)
BIOGRAPHY

Event Date & Time

Broadcast 1:
Date: 22 May 2024 Asia/ Europe
9 AM - 10:30 AM (London)
10 AM - 11:30 AM (Cape Town/ Central Africa/ CEST)
11 AM - 12:30 PM (Riyadh/ Istanbul)
1 PM - 2:30 PM (Islamabad)
12:30 PM - 2 PM (Kabul)
1:30 PM - 3 PM (New Delhi)
3 PM - 4:30 PM (Indonesia)
4 PM - 5:30 PM (Singapore/ Shanghai)
5 PM - 6.30 PM (Seoul/Tokyo)
6 PM - 7:30 PM (Melbourne)

Broadcast 2:
Date: 22 May 2024 LATAM/ America
9 AM - 10:30 AM (Los Angeles)
11 AM - 12:30 PM (Peru)
12 PM - 1:30 PM (New York)
1 PM - 2:30 PM (Sao Paulo)

Abstract

Join this webinar to learn from three accomplished leaders in the fight against TB:

Targeted NGS for Drug-resistant TB Detection: Evidence to Policy
Anita Suresh, Head of Genomics and Sequencing Unit, FIND, Geneva

Economic Analysis of Targeted NGS for Diagnosis of Drug-Resistant TB
Dr. Alice Zwerling, Associate Professor School of Epidemiology & Public Health, University of Ottawa, Canada

Practical Considerations for Implementing tNGS for DR-TB Detection in South Africa
Dr. Shaheed Vally Omar, Centre Head, Centre for Tuberculosis, National Institute for Communicable Disease, South Africa

Tuberculosis (TB) remains a leading global infectious disease killer, second only to COVID-19¹. It is an airborne disease caused by Mycobacterium tuberculosis bacteria and is responsible for infecting an estimated 10.6 million and killing 1.3 million people in 2022 alone¹. Gaps in detection and treatment of drug resistant TB (DR-TB) strains contribute to its continuation as a public health crisis¹. Targeted next-generation sequencing (tNGS) which provides comprehensive detection of DR-TB was recently recommended by WHO and can help address the gaps².

Learning Objectives

Discover studies and data demonstrating clinical accuracy, utility and cost effectiveness of tNGS for DR-TB detection.
Understand critical operational factors for successful tNGS implementation at a national level.

Webinars will be available for unlimited on-demand viewing after live event.

References:

1. Global tuberculosis report 2022. Geneva: World Health Organization; 2022. License: CC BY-NC-SA 3.0 IGO.

2. WHO Rapid Communication: Use of targeted next-generation sequencing to detect drug-resistant tuberculosis. July 2023 https://www.who.int/publications/i/item/9789240076372

Research Use Only. Not for use in diagnostic procedures. M-GL-02712